The effect of the glucocorticoid Oradexon on endotoxin-induced peritoneal cell response.
Glucocorticoids are important modulators of immune reactions. They are capable of antagonising several effects of the bacterial endotoxin by inhibiting endotoxin-induced leukocyte activation, and the production of cytokines and inflammatory mediators. We earlier demonstrated that the antiglucocorticoid RU 38486 enhances the cytokine production induced by endotoxin and aggravates the course of experimental endotoxic and septic shock. In the present study we investigated the effect of the glucocorticoid Oradexon on the endotoxin-induced peritoneal cell response. For measurement of the peritoneal cell response, male CFLP mice (20-25 g) were injected i.p. with 10 microg/10 g body weight endotoxin (E. coli 026:B6 LPS, Difco Lab, Detroit, lot 110273JB). Dexamethasone (Oradexon, N.V, Organon Oss, The Netherlands) was administered i.p., i.v. or s.c. in a dose of 0.1 mg/10 g body weight, alone or concomitantly with endotoxin. We found that bacterial endotoxin increased the total cell count due to neutrophilia at 24 hours and, due to increases in the number of macrophages and lymphocytes 48 and 72 hours after treatment, respectively. The i.p., i.v., and s.c. injection of Oradexon, increased the total cell count and the macrophage count at 24, 48 and 72 hours. The i.p., s.c. and i.v. injection of Oradexon, concomitantly with endotoxin, reduced the total cell count at 48 and 72 hours, due to decreases in the macrophage count. The i.p., i.v. or s.c. administration of Oradexon concomitantly with LPS decreased the lymphocyte count and the neutrophil count at 24 and 72 hours. These results prove that glucocorticoids are capable of modifying the immune cell reactions induced by endotoxin.
Szakács
J
J
Institute of Pathophysiology, Department of Surgery, Szent-Györgyi Albert Medical University, Szeged, Hungary.
Lázár
G
G
Lázár
G
G
Husztik
E
E
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology*; D004731:Endotoxins / Q000037:antagonists & inhibitors* / Q000633:toxicity; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects*; D018836:Inflammation Mediators / Q000378:metabolism*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000633:toxicity; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008262:Macrophage Activation / Q000187:drug effects*; D008297:Male; D051379:Mice; D020556:Neutrophil Infiltration / Q000187:drug effects; D010529:Peritoneal Cavity / Q000166:cytology
D000893:Anti-Inflammatory Agents; D004731:Endotoxins; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D003907:Dexamethasone